Clinical Trials
15
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:12
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
12 (80.0%)Not Applicable
3 (20.0%)Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Not Applicable
Recruiting
- Conditions
- Ovarian CancerOvarian CarcinomaOvarian SarcomaOvarian Cancer Stage IV
- Interventions
- Biological: GPC3 CD146 CAR-T cells
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 80
- Registration Number
- NCT07067255
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Not Applicable
Recruiting
- Conditions
- SarcomaSarcoma,Soft TissueSarcoma of Bone and Connective TissueSarcoma, SynovialSarcoma MetastaticSarcomas, GerminoblasticSarcoma, KaposiSarcoma, EwingSarcoma of Bone
- Interventions
- Biological: CD146/HER2 CAR-T cells
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT07066982
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
Not Applicable
Recruiting
- Conditions
- Pancreatic CancerPancreatic CarcinomaPancreatic Cancer Non-resectablePancreatic Cancer Stage IV
- Interventions
- Biological: Mesothelin and Claudin 18.2 CAR-T cells
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT07066995
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma ProgressionMultiple Myeloma, Refractory
- Interventions
- Biological: BCMA/GPRC5D CAR-T cells
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT07032129
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Phase 1
Recruiting
- Conditions
- Brain TumorBrain MetastasesBrain CancerGliomaGliomas, MalignantGlioblastomaMeningioma
- Interventions
- Biological: Tumor Infiltrating Lymphocytes (TIL)
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Essen Biotech
- Target Recruit Count
- 85
- Registration Number
- NCT06640582
- Locations
- 🇨🇳
District One Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- Next
News
No news found